NCT00806546

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 514 (actual)
• Sponsor: NuPathe Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	NP101	NP101 study patch four hour application

Timeline

• Start date: 2009-02-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2008-12-11
• Last updated: 2016-02-04
• Results posted: 2013-03-20

Locations

31 sites across 1 country: United States